Evidence map›Paper›PMID 39043682›Full record

Trial reportScientific reports2024

A randomised controlled trial of plasma exchange compared to standard of care in the treatment of severe COVID-19 infection (COVIPLEX).

Nishkantha Arulkumaran, Mari Thomas, Matthew Stubbs, Nithya Prasanna, Maryam Subhan, Deepak Singh, Gareth Ambler, Alessia Waller, Mervyn Singer, David Brealey and 1 more

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04623255 (A Randomised Controlled Trial of Plasma Exchange With Standard of Care Compared to Standard of Care Alone in the Treatment of Severe COVID-19 Infection), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04623255 phase2completednot on this map

A Randomised Controlled Trial of Plasma Exchange With Standard of Care Compared to Standard of Care Alone in the Treatment of Severe COVID-19 Infection (COVIPLEX)

TypeinterventionalSponsorUniversity College, LondonRan2020 to 2022Enrolled23ConditionsCOVID19ArmsOCTAPLAS
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Trial
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nishkantha ArulkumaranIntensive Care Unit, University College London Hospitals NHS Foundation Trust, London, UK.
Mari ThomasDepartment of Haematology, University College London Hospitals NHS Foundation Trust and Haematology Programme-NIHR UCLH/UC BRC London, 235 Euston Road, London, NW12PG, UK.
Matthew StubbsDepartment of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
Nithya PrasannaDepartment of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
Maryam SubhanDepartment of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
Deepak SinghSpecial Coagulation, UCLH-HSL, London, UK.
Gareth AmblerDepartment of Statistical Science, University College London, London, UK.
Alessia WallerIntensive Care Unit, University College London Hospitals NHS Foundation Trust, London, UK.
Mervyn SingerIntensive Care Unit, University College London Hospitals NHS Foundation Trust, London, UK.
David BrealeyIntensive Care Unit, University College London Hospitals NHS Foundation Trust, London, UK.
Marie ScullyDepartment of Haematology, University College London Hospitals NHS Foundation Trust and Haematology Programme-NIHR UCLH/UC BRC London, 235 Euston Road, London, NW12PG, UK. m.scully@nhs.net.

Funding

Medical Research Council MR/W030489/1
6 · The paper itself

Abstract

COVID-19 disease is associated with a hyperinflammatory, pro-thrombotic state and a high mortality. Our primary objective was to assess the change in inflammatory and thrombotic markers associated with PEX, and secondary objectives were to assess the effects of PEX on progression of respiratory failure and incidence of acute thrombotic events. We conducted a prospective, phase II, non-blinded randomised control trial of plasma exchange compared to standard of care in critically ill adults with severe COVID-19 associated respiratory failure, requiring supplemental oxygen or ventilatory support and elevated thrombo-inflammatory markers (LDH, CRP, ferritin, and D-Dimer). Patients randomised to receive PEX were treated with a daily single volume plasma exchange for a minimum of five days. Twenty-two patients were randomised of who 11 received PEX. Demographic and clinical characteristics were similar between groups at presentation. PEX was associated with a significant reduction in pro-thrombotic markers FVIII, VWF and VWF Ag: ADAMTS 13 ratio (p < 0.001). There were no differences in the reduction of inflammatory markers, severity of respiratory failure (p = 0.7), thrombotic events (p = 0.67), or mortality (p > 0.99) at 28 days. PEX successfully reduced pro-thrombotic markers, although was not associated with reduction in inflammatory markers, respiratory failure, or thrombotic events.Trial registration: (NCT04623255); first posted on 10/11/2020.

Indexed as

COVID-19Plasma ExchangeRespiratory InsufficiencyStandard of CareAdultAgedBiomarkersFemaleFibrin Fibrinogen Degradation ProductsHumansMaleMiddle AgedProspective StudiesSARS-CoV-2ThrombosisTreatment OutcomeBiomarkersFibrin Fibrinogen Degradation Productsfibrin fragment D

Identifiers

PMID39043682
PMCPMC11266620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.